De Plaen; Etienne

Patent Applications and Registrations

Patent applications and USPTO patent grants for De Plaen; Etienne.The latest application filed is for "trytophan catabolism in cancer treatment and diagnosis".

Company Profile

0.22.2

De Plaen; Etienne - Brussels N/A BE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Tumour rejection antigens Grant 8,519,109 - Huang , et al. August 27, 2	2013-08-27
Trytophan Catabolism In Cancer Treatment And Diagnosis App 20110159017 - Van Den Eynde; Benoit ; et al.	2011-06-30
Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3 Grant 7,923,534 - Boon , et al. April 12, 2	2011-04-12
Tumour Rejection Antigens App 20090209034 - Huang; Lan-Qing ; et al.	2009-08-20
Tumor rejection antigens Grant 7,547,439 - Huang , et al. June 16, 2	2009-06-16
Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor Grant RE40,089 - Boon-Falleur , et al. February 19, 2	2008-02-19
Method For Identifying Individuals Suffering From A Cellular Abnormality Some Of Whose Abnormal Cells Present Complexes Of Human Leukocyte Antigen Tyrosinase Derived Peptides, And Methods For Treating Said Individuals Grant 6,669,946 - Boon-Falleur , et al. December 30, 2	2003-12-30
Method for treating cancer by administering MAGE-derived peptides Grant 6,488,932 - Boon , et al. December 3, 2	2002-12-03
Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules Grant 6,379,901 - Boon-Falleur , et al. April 30, 2	2002-04-30
Isolated nonapeptides presented by HLA molecules, and uses thereof Grant 6,222,012 - Boon-Falleur , et al. April 24, 2	2001-04-24
Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors Grant 6,201,111 - Brichard , et al. March 13, 2	2001-03-13
Isolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cells Grant 6,034,214 - Boon , et al. March 7, 2	2000-03-07
Precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 6,001,975 - Brichard , et al. December 14, 1	1999-12-14
Tumor rejection antigen precursors, tumor rejection antigens and uses thereof Grant 5,925,729 - Boon , et al. July 20, 1	1999-07-20
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 5,856,091 - Brichard , et al. January 5, 1	1999-01-05
Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 5,854,203 - Brichard , et al. December 29, 1	1998-12-29
Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor Grant 5,837,476 - Brichard , et al. November 17, 1	1998-11-17
Isolated cytolytic T cells specific for complexes of MAGE related peptides and HLA molecules Grant 5,695,994 - Boon-Falleur , et al. December 9, 1	1997-12-09
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 Grant 5,620,886 - Brichard , et al. April 15, 1	1997-04-15
Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor Grant 5,612,201 - De Plaen , et al. March 18, 1	1997-03-18
Isolated nucleic acid molecules which encode MAGE derived nonapeptides Grant 5,462,871 - Boon-Falleur , et al. October 31, 1	1995-10-31
Isolated nonapeptides derived from MAGE genes and uses thereof Grant 5,405,940 - Boon , et al. April 11, 1	1995-04-11
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 Grant 5,342,774 - Boon , et al. August 30, 1	1994-08-30

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.